Eunice Wang, MD
At the 2017 European Hematology Association (EHA) Congress, Eunice Wang, MD, presented an abstract examining the biology of newly diagnosed patients with FLT3
-positive acute myeloid leukemia (AML) who achieved a response to the FLT3 tyrosine kinase inhibitor (TKI) crenolanib combined with chemotherapy.
at EHA, Wang, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discussed her research and the next steps for crenolanib and other emerging FLT3 inhibitors in AML.
OncLive: Please provide an overview of the study.
This is actually a follow-up of a phase II clinical trial that was presented at the ASH 2016 Annual Meeting. In this trial, we combined crenolanib, which is a novel potent type 1 receptor TKI FLT3 with standard chemotherapy for the treatment of newly-diagnosed FLT3 mutant patients with AML.
... to read the full story